Executive Director, Global Strategic Insights at Axsome Therapeutics Inc

United States

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, PharmaceuticalsIndustries

Requirements

Candidates must be able to maximize all data sources, including market research and CRM, and effectively communicate their results and applications. A strong understanding of the competitive intelligence environment for current and pipeline products from a business perspective is essential. The role requires the ability to support brand leaders, sales, market access, and other functions with forecasting and performance metrics.

Responsibilities

This position leads the Global Strategic Insights function, responsible for generating business insights, market research, and competitive intelligence for current and future products. Key duties include leading the annual forecast and long-range planning processes for global revenue and expenses, conducting commercial assessments for business development, and managing the analytics dashboard. The role serves as a liaison for forecasting and data analytics, supports the Global Brand Planning process, leads global CRM implementation, and provides ad-hoc analytical support to marketing and sales efforts. The individual will also stay updated on emerging industry data sources and techniques and ensure adherence to regulatory requirements and SOPs.

Skills

Business Insights

Analytics

Decision Support

Business Planning

Market Research

Advanced Analytical Tools

KPIs

Dashboards

Data Analysis

Customer Behavior Analysis

Prescription Growth

Revenue Growth

Business Development

Stakeholder Engagement

Performance Management

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free